Paraoxonase 1 (PON1) is a calcium-dependent hydrolase associated with serum high-density lipoprotein particles. PON1 hydrolyzes some organophosphates (OPs), including some nerve agents, through nucleophilic attack of hydroxide ion (from water) in the active site. Most OPs are hydrolyzed inefficiently. This project seeks to identify nucleophiles that can enhance PON1-mediated OP degradation. A series of novel nucleophiles, substituted phenoxyalkyl pyridinium oximes, has been synthesized which enhance the degradation of surrogates of sarin (nitrophenyl isopropyl methylphosphonate; NIMP) and VX (nitrophenyl ethyl methylphosphonate; NEMP). Two types of in vitro assays have been conducted, a direct assay using millimolar concentrations of substrate with direct spectrophotometric quantitation of a hydrolysis product (4-nitrophenol) and an indirect assay using submicromolar concentrations of substrate with quantitation by the level of inhibition of an exogenous source of acetylcholinesterase from non-hydrolyzed substrate. Neither NIMP nor NEMP is hydrolyzed effectively by PON1 if one of these novel oximes is absent. However, in the presence of eight novel oximes, PON1-mediated degradation of both surrogates occurs. Computational modeling has created a model of PON1 embedded in phospholipid and has indicated general agreement of the binding enthalpies with the relative efficacy as PON1 enhancers. PON1 enhancement of degradation of OPs could be a unique and unprecedented mechanism of antidotal action.
Paraoxonase 1 (PON1) is a calcium-dependent hydrolase known to be able to hydrolyze a variety of organophosphate (OP) triesters, including nerve agents, insecticides, or insecticidal metabolites, as well as model compounds. PON1 is one of three paraoxonases (also including PON2 and PON3) whose genes occur in close proximity on human chromosome 7 (Ng et al., 2005) .
However, PON1 is the only 1 of the 3 PON's which hydrolyzes OPs, and therefore it is the one which has been most studied and is the one of relevance to the present study on destruction of OPs. Paraoxonase was originally named, before its endogenous function was known, for its ability to hydrolyze paraoxon (the active anticholinesterase metabolite of the insecticide parathion, formed by cytochromes P450, CYPs; Neal, 1967) . PON was characterized by Aldridge (1953) many years ago as an A-esterase, a hydrolase that was not inhibited by paraoxon and in fact could hydrolyze paraoxon. PON1 is synthesized in the liver and secreted into the bloodstream and is associated with serum high-density lipoprotein (HDL) particles (Harel et al., 2004) . PON1 functions normally as a lipolactonase that hydrolyzes oxidized (damaged) lipids and thereby affords protection from atherosclerosis and cardiovascular disease (Harel et al., 2004; Martinelli et al., 2009) .
Because OP hydrolysis is only a coincidental, and not the primary, function of PON1, most OPs are inefficiently hydrolyzed, including the nerve agents and, ironically, paraoxon (for which the enzyme was named). When OPs are positioned within PON1's active site, an amino acid (such as histidine) in close proximity to the OP deprotonates a water molecule to produce a hydroxide ion, which performs a nucleophilic attack on the phosphorus and hydrolyzes the OP. Substantial work has been done on characterizing the configuration and the amino acid residues in and around the active site of PON1 (Aviram et al., 1998; Josse et al., 2001; Sorenson et al., 1995) . The mechanism of this hydrolysis suggested by computational modeling probably does not involve covalent bond formation between the OP and the enzyme Peterson et al., 2011; Sanan et al., 2010) . For most OP substrates, this hydroxide ion-mediated hydrolysis is relatively slow and inefficient, so turnover is low, largely because the hydroxide ion is only a moderately strong nucleophile. Chlorpyrifos-oxon and diazoxon, the active metabolites of the insecticides chlorpyrifos and diazinon, respectively, are among the very few OP molecules hydrolyzed by PON1 very efficiently, whereas paraoxon, the active metabolite of parathion, is not metabolized efficiently (Pond et al., 1996; Richter and Furlong, 1999) . Among the nerve agents, soman is hydrolyzed more efficiently than sarin, and VX is metabolized only poorly (Kirby et al., 2013; Rochu et al., 2007) .
Although a number of attempts to identify chemicals that enhance PON1 activity have been made, including dietary components as well as exogenous chemicals, as reviewed by Costa et al. (2011) , these studies have been in intact animals or cell cultures and reflect potential enhancement of gene expression and therefore increased PON1 activity by virtue of increasing the amount of PON1 protein. Existing studies, to our knowledge, have not identified small molecule enhancers.
The objective of the present in vitro study was to investigate potential enhancers that can increase the ability of PON1 to detoxify toxic OP anticholinesterases. The chemistries examined are hypothesized to be nucleophilic small molecules that can more effectively cleave OP molecules within the active site of PON1 than can the hydroxide ion formed from water within the active site. The substrates used for PON1 were paraoxon and surrogates for sarin and VX that our laboratories have synthesized and used in acetylcholinesterase (AChE) reactivation studies Meek et al., 2012) . The nucleophiles synthesized and tested here were primarily oximes, which are known to be strong nucleophiles, and are of a similar series to the novel oximes synthesized earlier as reactivators . Computational modeling was conducted to provide better insights into the binding of the substrates and proposed enhancers into the PON1 active site and to provide a model of an important PON1 polymorphism that influences substrate binding. The overall goal of the present study was to identify nucleophiles that can enhance PON1-mediated detoxication of OPs which might have potential to be developed as antidotes to nerve agent exposure through a therapeutic mechanism that, to our knowledge, would be unprecedented.
MATERIALS AND METHODS
Materials. Chemicals for synthesis and biochemicals and reagents for the PON1 assays were purchased from Sigma-Aldrich, St Louis, Missouri. Commercially available pooled human serum was obtained from Innovative Research, Novi, Michigan.
OP substrate synthesis. Surrogates of sarin (nitrophenyl isopropyl methylphosphonate; NIMP) and VX (nitrophenyl ethyl methylphosphonate; NEMP) were synthesized using methods previously described (Meek et al., 2012) . These surrogates substitute 4-nitrophenol for the leaving groups of sarin and VX, and therefore they substantially resemble their respective nerve agents. Briefly, for NIMP, methylphosphonic dichloride was reacted sequentially with 4-nitrophenol and with isopropyl alcohol in dichloromethane plus triethylamine. For NEMP, the procedure was identical to that for NIMP except that ethanol was used in the second step rather than isopropyl alcohol.
Paraoxon was synthesized as previously described (Chambers and Chambers, 1989) . Briefly, conditions used were similar to those described above for NIMP except that only a single step was involved. Diethyl chlorophosphate was reacted with 4-nitrophenol in dichloromethane in the presence of triethylamine. These substrates and their hydrolysis products are shown in Figure 1 .
Nucleophile synthesis and characterization. Two types of nucleophiles (neutral or charged) were selected for testing. Neutral nucleophiles were either obtained from Sigma-Aldrich or synthesized in our laboratories. Neutral nucleophiles either were commercially available hydrazones or were benzaldehyde oximes, some of which were commercially available. For synthesis of additional neutral oximes, appropriate aldehydes or ketones were refluxed with 1.5 equivalents of hydroxylamineHCl in ethanol. When most of the aldehyde or ketone had reacted, as determined by thin layer chromatography (TLC), the ethanol was evaporated. The product was purified by recrystallization from hexane until a single spot on TLC was obtained.
The charged nucleophiles tested were substituted phenoxyalkyl pyridinium oximes (patent pending), synthesized as previously described . The generic structure of the series of novel substituted phenoxyalkyl pyridinium oximes is presented in Figure 2 . Briefly for the oximes with a linker chain length of 6, oximes were prepared by similar 2-step reactions to those described above. Initially, the appropriate phenol was refluxed about 12 h with 1,6-dibromohexane (1.5 molar excess) in acetonitrile over anhydrous K 2 CO 3 . Following filtration and removal of solvent, the phenoxyhexyl bromide was recrystallized from hexane or methanol depending on the intermediate's solubility. The phenoxyhexyl bromide was then refluxed with pyridine-4-aldoxime in acetonitrile until a significant precipitate was visible (typically 1-2 days). The mixture was cooled and filtered. The solid product was recrystallized from ethanol or methyl ethyl ketone, depending on the product's solubility.
As will be described below, in total, 121 nucleophiles were tested, with 8 of these showing efficacy in the in vitro screening experiments. The 8 effective compounds, all of which were substituted phenoxyalkyl pyridinium oximes with a linker chain length of 6, were further characterized by high-resolution mass spectrometry (MS) and nuclear magnetic resonance (NMR), similar to methods described earlier (Meek et al., 2012) .
MS analysis. Electrospray ionization mass spectral analyses of the oximes were performed on a Bruker MicrOTOF-QII mass spectrometer using the positive-ion mode. Solutions (approximately 5 lM) of the samples (in HPLC grade methanol) were electrosprayed, and the relative total ion abundance (m/z ¼ approximately 100-1500) was measured using the following parameters: capillary voltage, þ 4500 V; dry gas, 4.0 l/min; dry temperature, 180 C; collision energy, 8.0 eV; and flow rate, 300 ml/h. Direct assay of PON1-mediated degradation of substrates. PON1 hydrolysis of high concentrations of NIMP (0.3 mM), NEMP (0.3 mM), or paraoxon (1.2 mM), both with and without novel nucleophiles, was determined by measuring the product 4-nitrophenol spectrophotometrically using the method described by Richter and Furlong (1999) as modified in our laboratories (Davis et al., 2009) . Nucleophiles were dissolved in ethanol and were incubated for 15 min in a 0.05 M Tris-HCl buffer, pH 7.4 at 37 C, at a final concentration of 0.1 mM (as adjusted for purity as determined by NMR), both with and without human serum. Parallel subsamples were assayed containing either 2 mM CaCl 2 (to stimulate PON1 activity) or 1 mM EDTA (to inhibit PON1 activity). The assays conducted without serum were to account for any chemical-chemical interactions. Tris base containing 2.0 mM EDTA was added to alkalinize and terminate the PON1 reaction, and absorbance of 4-nitrophenol was read at 405 nm. At least 3 independent repetitions for each enhancer were conducted. Because of the higher throughput using this direct assay, all 121 available potential enhancers were screened with the direct assay, and only a subset was assayed with the indirect assay described below. Data were analyzed by paired t tests, comparing the calcium-adjusted activities for samples containing serum, surrogate, and test nucleophile to their corresponding activities containing serum and surrogate only.
Indirect PON1 assay. Assay of PON1 at submicromolar OP concentrations was accomplished by using inhibition of an exogenous source of AChE (bovine brain) to quantify residual OP following incubation of the OP in human serum containing either 2 mM CaCl 2 (to stimulate PON1 activity) or 1 mM EDTA (to inhibit PON1 activity) using some modifications of our method described earlier (Chambers et al., 1994) . OPs were used at concentrations which would yield 80%-90% inhibition of the AChE following incubation in buffer without serum. These concentrations were: NEMP (30 nM), NIMP (160 nM), or paraoxon (200 nM). Incubation was conducted for 30 min of the OP in 1.5 ml serum dilution (10 ml/ml in 0.05 M Tris buffer, pH 7.4) containing either 2 mM CaCl 2 or 1 mM EDTA. Parallel incubations were conducted for serum alone and for serum plus 0.1 mM test nucleophile (adjusted for purity as indicated by NMR). Following this first incubation 500 ml of bovine brain homogenate (100 mg/ml) was added for a total volume of 2 ml and incubation was conducted for another 15 min to allow non-hydrolyzed OP to inhibit AChE. The preparation was then diluted 10-fold and AChE activity was determined using acetylthiocholine as substrate in a modified Ellman assay (Ellman et al., 1961; Chambers and Chambers, 1989) . A 15-min incubation with 1 mM acetylthiocholine was followed by an addition of 5% sodium dodecyl sulfate/ 2.6 mM 5,5 0 -dithio bis(nitrobenzoic acid). Absorbance was quantified at 412 nm. Results were expressed as the difference between the reduction of AChE inhibition with and without nucleophile. Under these assay conditions, no differences in AChE inhibition were observed between the serum plus Ca 2þ samples and the serum plus EDTA samples in the absence of one of the 8 effective nucleophiles.
Since percent inhibition of AChE is a reflection of residual OP concentration, a decrease in percent AChE inhibition in serum plus Ca 2þ compared with serum plus EDTA is an indication of PON1 activity. Percent differences between an assay with nucleophile and Ca 2þ compared with an assay with nucleophile and EDTA provided a measure of the effectiveness of the nucleophile in enhancing PON1 activity. For nucleophiles yielding more than a 10% decrease in AChE inhibition, a minimum of 3 assays were conducted. Because there was no measureable activity in assays without nucleophiles, statistical significance was assessed for assays containing nucleophiles by determining whether the interval of mean percent decrease 6 2 standard deviations included zero, since this interval should contain 95% of the population.
Computational modeling. The primary sequence of PON1 was obtained from the UniportKB/Swiss-Port server and was submitted to the SWISS-MODEL online server which generated the tertiary structure of Q192 PON1 using PDB ID: 3SRG as a reference template. The H1 loop, missing in the crystal structure, was generated using the MODELLER program and was attached to the modeled PON1 structure. The modeled structure was initially minimized and then heated using Amber 12 and the ff99SB force field (Hornak et al., 2006) with a cutoff of 12 Å . Further, the enzyme was equilibrated for 1 ns and then cooled to 0 K. These initial calculations all used an implicit solvent model. The resultant annealed structure was submitted to the Hþþ server to obtain the protonation states of the titratable residues and the total charge of the protein.
Explicit solvent model simulations were performed using the ff99SB force field on the protein structures generated by Hþþ. The protein was placed in a rectangular box and solvated with TIP3P waters. It was then neutralized by adding 10 Na þ ions and minimized. Subsequently, the system was heated for 50 ps from 10 K to 300 K under NVT (constant number of particles, volume, and temperature) conditions with a force constant of 10 kcal mol À1 Å À2 on the protein and then equilibrated for 450 ps at 300 K under NPT (constant number of particles, pressure, and temperature) conditions. Finally, it was sampled for 40 ns under NVT conditions. During the equilibration and sampling processes, the hydrogens were constrained using the SHAKE algorithm, and a constant temperature was maintained using Langevin dynamics with a collision frequency of 1.0 ps
À1
. The long-range electrostatic interactions were handled using Particle Mesh Ewald under periodic boundary conditions with a 12-Å cutoff. These simulations were performed with a time step of 1 fs.
From the last nanoseconds of the sampling process, a snapshot was generated, and the solvent molecules and Na þ ions were removed. The H1 loop was deleted from the generated snapshot and rebuilt as an ideal alpha helix using Spartan 0 10.
The redesigned loop was attached to the generated snapshot. Palmitoyl-oleoyl phosphatidylcholine (POPC) was chosen as a lipid bilayer model and was constructed using VMD. The protein was aligned perpendicular to the lipid bilayer, and the H1 loop was inserted into the bilayer. Finally, the system was capped with a solvent box, and 10 Na þ ions were added to neutralize the system. The final unit cell contained 378 POPC molecules and 41 378 water molecules. The surface of an HDL particle consists of a lipid layer. Since modeling the entire HDL particle is intractable, we have represented the surface of the particle with the lipid bilayer. The minimization, heating, equilibration, and sampling were done using the ff99SB and Lipid11 (Skjevik et al., 2012) force fields. After minimization, the system was quickly heated (10-100 K) for 20 ps under NVT. Next, it was heated (100-300 K) for 100 ps under NPT. The rest of the simulation was performed under NPT conditions. The initial 10 ns of the equilibration process were performed with a constraint force constant of 1.0 kcal mol À1 Å À2 on the protein. The next 15 ns of the simulation were performed with a force constant of 1.0 kcal mol À1 Å
À2
on the protein and a constant surface tension of 15.0 dyne cm À1 on the membrane. Finally, the system was equilibrated for another 55 ns using the constant surface tension on the membrane and no constraint on the protein. After removing K þ and Cl À ions that had crystallized, the entire system was sampled for another 40 ns. The model constructed was then used to characterize interactions between the two nerve agent surrogates (NIMP and NEMP) and some of the novel oximes shown to have some efficacy in the in vitro assays. Partial atomic charges for NIMP, NEMP, and the novel oximes were generated using HF/6-31G* calculations and the restrained electrostatic potential approach (Bayly et al., 1993) . NIMP and NEMP were docked into 20 snapshots chosen from the last 10 ns of simulation on the PON1þPOPC system using Autodock Vina (Trott and Olson, 2010) . The docked structures with the smallest distances between the O in the P ¼ O of the NIMP/NEMP and the catalytic Ca 2þ of PON1 were chosen for further simulations.
Explicit solvent model simulations were performed using the same force fields as previously. The selected structures were placed in a rectangular box, were neutralized by adding 10 Na þ ions, and were solvated with TIP3P model water molecules.
After minimization and heating, the systems were sampled for 50 ns with a constant surface tension of 15.0 dyne cm À1 on the membrane. Dynamics were performed with a time step of 2 fs. Five of the monopyridinium oximes that showed activity in the assays were docked into four snapshots each of the NIMPþPON1þPOPC and NEMPþPON1þPOPC systems, and the best docked structures were then simulated for at least another 50 ns using the procedures described above. Finally, 100 snapshots from the last 10 ns of simulation were used to calculate binding enthalpies for each oxime using the molecular mechanics-generalized Born-surface area (MM-GBSA) approach.
RESULTS
Initially, commercially available and synthesized uncharged nucleophiles were tested as potential PON1 enhancers. Eight hydrazones and 22 oximes were tested in both the direct and indirect assays, and none of these neutral nucleophiles were effective at enhancing PON1 detoxication of NIMP or NEMP. Representative examples of these neutral nucleophiles include acetaldehyde oxime, pyruvic aldehyde oxime, acetone oxime, cyclohexanone oxime, benzaldehyde oxime, acetophenone oxime, isonitrosopropiophenone, and 4-nitrobenzaldehyde oxime.
A series of 93 novel substituted phenoxyalkyl pyridinium oximes (generic structure shown in Fig. 2 ) with a linker chain length of 3, 4, or 5 and with various substitutions were tested in the direct assay with NIMP, NEMP, and paraoxon. None of these were effective in enhancing PON1 activity with any of the substrates. Because most of these novel oximes with these chain lengths are reasonably effective reactivators of phosphylated AChE , these oximes could not be tested in the indirect assay. Many of these structures were reported on earlier as AChE reactivators .
Three novel oximes with a linker chain length of 6 showed substantial efficacy in the direct assay with NIMP and/or NEMP, but not with paraoxon (Fig. 3) . Numbers 4, 5, and 7 yielded 20%-40% enhancement with both substrates, whereas numbers 1 and 6 yielded 5%-10% enhancement with NEMP only. These oximes with a linker chain length of 6 are not effective AChE reactivators, so they were tested in the indirect assay, and 8 novel oximes showed efficacy with NIMP and NEMP, but not with paraoxon (Fig. 4) . All showed some efficacy in the range of about 10%-35% enhancement, with numbers 4, 5, and 7 being the most efficacious with both NIMP and NEMP. It is noteworthy that PON1 does not provide any measureable detoxication of NIMP, NEMP, or paraoxon in the indirect assay in the absence of one of these oximes. The structures of these 8 effective oximes are shown in Figure 5 . The various controls employed in both the direct and indirect assays guarantee that the observed activities and enhancement result from PON1 as well as from the action of the oxime: the activities are the difference between the Ca 2þ -containing and the EDTA-containing tubes, indicating that the observed activities were the result of PON1; there were parallel assays without serum to account for any chemicalchemical interactions between the substrate and the oxime (there were none); and the activities are the difference between the assays with oxime compared with the assays without oxime (and there was no measurable PON1 activity with any of the three substrates in the indirect assay when the oxime was absent).
Two oximes with a linker chain length of 8 were slightly effective in the indirect assay, but were not as effective as those with a linker chain length of 6. A few oximes with a linker chain length of 10 or 12 were tested in both the direct and indirect assays, and were ineffective. Therefore, a larger number of these longer oximes were not synthesized. Table 1 lists the calculated binding enthalpies (DH) for 5 of the oximes which were shown to be effective in the indirect assay. MM-GBSA absolute DH values are often too negative; however, the relative values generally are meaningful. All of the oximes have a very negative DH, and therefore they are all predicted to bind efficiently to PON1 once an OP is in the active site. In addition, the oxime moieties are similar electronically in all of the phenoxyalkyl pyridinium oximes. Hence, the calculations predict that the modeled oximes should have similar efficacy, which they showed in the indirect assay (Fig. 4) .
DISCUSSION
Paraoxonase, despite being named for its ability to hydrolyze the OP paraoxon, is relatively inefficient at detoxifying most OPs. Serum PON1 represents one of the first lines of defense available for any absorbed OPs. For this reason other laboratories are developing recombinant PON1s that have inherently better catalytic efficiency than native PON1 . Although there are other defenses in the blood against OP anticholinesterases, such as serum butyrylcholinesterase or erythrocyte AChE, these serine esterases are persistently inhibited by the OPs, are saturable, and therefore represent a stoichiometric detoxication mechanism that has a limited capacity to destroy circulating OP. In contrast PON1 detoxifies catalytically and would not likely be saturable at most potential exposure levels. Therefore, any enhancer that could improve the catalytic efficiency of PON1 toward its substrates could assist in reducing the circulating levels of OP anticholinesterases and reduce or potentially eliminate OP toxicity. Because the mechanism of PON1-mediated catalysis involves the attack on phosphorus by the nucleophilic hydroxide ion formed in the active site, the hypothesis guiding this project was that a more potent oxime that fits into the PON1 active site effectively could enhance the turnover of OP substrates by PON1. Because of the knowledge of PON1 from crystal structure computational analysis (David et al., 2012) , our initial thinking was that a non-charged oxime might better insert itself into the active site than would a charged nucleophile. However, all of the hydrazones and benzaldehyde oximes tested were ineffective as enhancers. The next series of nucleophiles tested were the novel substituted phenoxyalkyl pyridinium oximes that were developed in our laboratories as potential brain-penetrating AChE reactivators . The series of novel oximes with a linker length of 3, 4, or 5 are effective AChE reactivators, so a large number of these were available. The novel oximes with a linker length of 6 were not effective AChE reactivators, so few were already available and most (including all that showed efficacy) were synthesized in the present study. Although the substituted phenoxyalkyl pyridinium oximes with a linker chain length of 3, 4, or 5 were ineffective as PON1 enhancers, 8 oximes with a chain length of 6 were effective in the indirect assay. Longer chain lengths of 8, 10, or 12 were also not effective. Therefore, the chain length of 6 seems to be the most suitable length for interacting in the active site. Although it is not known why efficacy was observed for 8 oximes in the indirect assay and for essentially only 3 in the direct assay, the most likely explanation is that the relatively low amounts of product formed in the presence of some of the enhancers could have been below the limits of quantitation of the spectrophotometric assay.
Our docking studies on oximes with shorter and longer chains are consistent with the results of the in vitro assays, suggesting that a chain length of 6 is optimal to allow the oxime moiety to attack the OP in the active site, whereas the lipophilic end of the oxime interacts with the lipid layer (Bhavaraju, 2013) . These substituted phenoxyalkyl pyridinium oximes are expected to be quite lipophilic and are expected to be attracted to the lipids of the HDL particle where PON1 resides, as seen in Figure 6 . The binding enthalpies calculated from the human PON1 model inserted into a lipid bilayer in which either NIMP or NEMP was docked are generally proportional to the effectiveness observed by the novel nucleophiles in enhancing PON1-mediated detoxication of NIMP or NEMP in the indirect assay.
We wish to note that one possible reaction with any oximes that are tested is the potential AChE inhibitory ability of oximephosphates that are formed as the result of the nucleophilic attack by the oxime on the phosphorus of the OP. Such oxime phosphates are known from the oximes used as AChE reactivators and are very potent AChE inhibitors in some cases (Luo et al., 1999) . Any oximes forming potent and stable oxime phosphates would be unacceptable as antidotes. Our indirect assay method allowed us to easily screen out any oxime nucleophiles that are likely to form toxic oxime phosphates because AChE inhibition is the basis of the quantitation in the assay. If any inhibitory oxime phosphates were formed, they inhibited the AChE in the reaction mixture, so no reduction in AChE inhibition, and perhaps even an increase in AChE inhibition, would be observed and the test compound would be rejected. We assume at this point that the several oximes that were efficacious as PON1 enhancers formed oxime phosphates that were very unstable, that had weak anticholinesterase potency, or that were not bioavailable. These possibilities will be subjects for our ongoing investigations. The present study represents the first report, to our knowledge, of small molecule enhancers of PON1 activity in the detoxication of OPs. Although oximes are usually known for their ability to reactivate phosphylated AChE, their reactivation ability relies on the fact that they are nucleophiles that can attack the phosphorus inhibiting the serine in the AChE active site to result in a transphosphorylation reaction, thus liberating the AChE active site serine.
The novel oximes that were effective here are relatively large and lipophilic, with 6 carbons being the only linker chain length that demonstrated reasonable efficacy for PON1 enhancement. The computational modeling showed that the active site of human PON1, when embedded in a lipid bilayer, appears to be substantially larger than the active site of the recombinant PON1 crystal structure in solution (Bhavaraju, 2013) . Therefore our novel oximes, while relatively large, can be reasonably predicted to fit into this larger active site.
The computational modeling presents a more biologically relevant model for human PON1 by embedding the structure into lipid, similar to the natural state in which PON1 is embedded in the HDL particle. The human PON1 model constructed here allowed calculation of binding enthalpies that were consistent with the enhancement efficacy observed in the PON1 indirect assay. Future modeling will involve the construction of the R192 PON1, the other common PON1 active site polymorphism, for testing with these novel oximes.
The effective novel nucleophiles have specificity for the two nerve agent surrogates and not paraoxon. This is similar to the specificity displayed by many AChE reactivating oximes that can reactivate AChE inhibited by some but not all OP anticholinesterases (Antonijevic and Stojiljkovic, 2007) .
Although considerably more research is needed on these compounds to determine efficacy in vivo, kinetic characteristics, testing with serum displaying a single PON1 Q192R polymorphism, testing purified or recombinant PON1 and testing with actual nerve agents, these initial observations are highly promising for identifying a new series of nucleophiles that have potential as nerve agent therapeutics through a unique mechanism of action, ie, enhancement of PON1-mediated detoxication.
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